MedTrace Logo

Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!

NCT06608186 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-01-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if drospirenone can work to prevent LH surge in controlled ovarian stimulation in PCOS cases undergoing ART cycles. The main questions it aims to answer are:

Can drospirenone prevent LH surge in controlled ovarian stimulation in PCOS cases ? Can it prevent the occurance of ovarian hyperstimulation?

Researchers will compare drospirenone to cetrorelix (A well known drug for such cases) to see if drospirenone works the same way.

Participants will:

Take drospirenone or cetrorelix from stimulation day 5 ( 5 days of ovarian stimulation) till day of hCG trigger

\- monitoring will be done before the cycle and through the cycles with vaginal ultrasound assessment and lab testing

Conditions

  • PCOS (Polycystic Ovary Syndrome)

Interventions

DRUG

Cetrorelix drug

a drug injection daily sc. from day 5 of stimulation till hCG trigger day

DRUG

Drospirenone drug

A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day

Sponsors & Collaborators

  • Ahmed Saad

    lead OTHER

Principal Investigators

  • Ahmed s saad, phD · Professor of OB & GYN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2025-01-19
Completion
2025-01-19

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06608186 on ClinicalTrials.gov